Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 490 | 80 | 380 |
| Samples | 208 | 51 | 153 |
| Peptides | 164 | 33 | 122 |
Function
CCR5 · C-C motif chemokine receptor 5
This gene encodes a member of the beta chemokine receptor family, which is predicted to be a seven transmembrane protein similar to G protein-coupled receptors. This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. Defective alleles of this gene have been associated with the HIV infection resistance. The ligands of this receptor include monocyte chemoattractant protein 2 (MCP-2), macrophage inflammatory protein 1 alpha (MIP-1 alpha), macrophage inflammatory protein 1 beta (MIP-1 beta) and regulated on activation normal T expressed and secreted protein (RANTES). Expression of this gene was also detected in a promyeloblastic cell line, suggesting that this protein may play a role in granulocyte lineage proliferation and differentiation. This gene is located at the chemokine receptor gene cluster region. An allelic polymorphism in this gene results in both functional and non-functional alleles; the reference genome represents the functional allele. Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2015].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 164 amino-acid changes on canonical ENST00000292303 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CCR5 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CCR5 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 7/612 1% |
| Melanoma | 6/210 3% | 26/1899 1% |
| Glioma | 1/52 2% | 23/2127 1% |
| Germ Cell Tumour | 2/25 8% | 0/169 0% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Colorectal Carcinoma | 6/143 4% | 25/3239 1% |
| Gastric Carcinoma | 0/74 0% | 17/1809 1% |
| Ovarian Carcinoma | 1/109 1% | 6/998 1% |
| Bladder Carcinoma | 1/58 2% | 5/956 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 3/810 0% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 6/1390 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Other Solid Cancers | 1/94 1% | 6/1515 0% |
| Prostate Carcinoma | 0/13 0% | 6/2105 0% |
| Other Sarcomas | 2/69 3% | 0/699 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Hepatocellular Carcinoma | 2/46 4% | 3/2210 0% |
| Kidney Carcinoma | 0/85 0% | 4/1862 0% |
| Head and Neck Carcinoma | 0/85 0% | 3/1574 0% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 1/2550 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 4/2534 0% |
| Breast Carcinoma | 2/144 1% | 3/3264 0% |
| Neuroendocrine Tumour | 1/154 1% | 0/577 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
Mutation Distribution
Where CCR5 is mutated · all tissues, split by cell line vs tissue
How many mutations in CCR5 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 490 mutations in CCR5
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|